1-3 of 3
Jeffery Lancet, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.

Azra Raza, MD, Magda Melcert, MD, Naomi Galili, PhD, Scott E. Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Shelby Young, RN, Lisa Meng, MS, Marsha Jones, MD, Gail L. Brown, MD, Jeffery Lancet, MD, Alan List, MD
Journal: Blood
Blood (2007) 110 (11): 1454.
https://doi.org/10.1182/blood.V110.11.1454.1454
Published: 2007
Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.

Teresa Field, MD, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Hugo Fernandez, MD, William Janssen, PhD, Mohammed Karfan-Dabaja, MD, Jeffery Lancet, MD, Mafda Melchert, MD, Jyoti Raychaudhuri, MD, Daniel Sullivan, MD, Alan List, MD, Claudio Anasetti, MD, William Poling, PhD, Janelle Perkins, PharmD
Journal: Blood
Blood (2007) 110 (11): 5035.
https://doi.org/10.1182/blood.V110.11.5035.5035
Published: 2007
Journal Articles

Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS).

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Melissa Alsina, MD, Ernesto Ayala, MD, Hugo F. Fernandez, MD, William Janssen, PhD, Mohamed Kharfan-Dabaja, MD, Jeffery Lancet, MD, Lia Perez, MD, Daniel Sullivan, MD, Alan List, MD, Claudio Anasetti, MD
Journal: Blood
Blood (2006) 108 (11): 3664.
https://doi.org/10.1182/blood.V108.11.3664.3664
Published: 2006